Skip to main content
. Author manuscript; available in PMC: 2024 Jun 6.
Published in final edited form as: Arthritis Care Res (Hoboken). 2023 Nov 27;76(3):328–339. doi: 10.1002/acr.25234

Figure 2.

Figure 2.

Medication use by patients with SJIA-LD before and after LD diagnosis, separated into (A) medications routinely used for SJIA, (B) other immunomodulatory therapy, and (C) treatments for pulmonary disease and prophylaxis. *P < 0.05, **P < 0.01, ***P < 0.001 compared with pre-LD diagnosis. IVIG, intravenous immunoglobulin; LABA, long-acting beta agonist; LD, lung disease; MMF, mycophenolate mofetil; SABA, short-acting beta agonist; SJIA, systemic juvenile idiopathic arthritis; TMP/SMIX, trimethoprim-sulfamethoxazole.